<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Biodesix Announces New Commercial Organization and Executive Appointments

Biodesix, Inc., a leading diagnostic company in lung cancer, today announced the realignment of their commercial executive team. Kieran O’Kane will be promoted to Chief Commercial Officer (CCO) and Bobbi Coffin, current Chief Marketing Officer, will become the Chief Growth Officer (CGO), effective immediately.

Biodesix Strengthens Lung Nodule Testing Strategy with the Nodify CDT™ Test

Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT™ test, designed to help physicians identify patients with lung nodules at high risk of lung cancer.

Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.

Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.

Biodesix Partners with Streck to Support In Vitro Diagnostic (IVD) Strategy

Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.

AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

AVEO Oncology and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab. Learn More!

Biodesix Named Company of the Year by Colorado BioScience Association

Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association. The company was honored at the 16th Annual CBSA Awards Dinner.

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study

AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.

Biodesix Appoints Scott Hutton as Chief Executive Officer

Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.

Biodesix Announces First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management

Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.

Biodesix Completes Acquisition of Oncimmune Assets in the United States

Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.

First 1 2 3 4 5 6 7 8 9 Last